Inselspital Bern (Department for Visceral Surgery and Medicine)
Bern, 3010, Switzerland
NCT Number: NCT04737642
To investigate feasibility and safety of intraoperative bile duct clearance by sphincter of Oddi balloon dilatation via cystic duct at cholecystectomy.
Primary endpoint: rate of successful bile duct stone clearance (feasibility). Secondary endpoints (safety): rate of peri-interventional complications (injury to the common bile duct, bleeding, injury to surrounding organs: stomach, duodenum, liver) and short-term postoperative complications (bile leak, cholangitis, lipasaemia, pancreatitis, pneumonia). Duration of procedure. Length of hospital stay.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Bern, 3010, Switzerland
Standard approach to address common bile duct stones is endoscopic retrograde cholangiography (ERC) with sphincterotomy. Those interventions are performed either before or after gallbladder removal (cholecystectomy), thus, requiring at least two interventions. Moreover, ERC with sphincterotomy is associated with a considerable rate of short and long-term morbidity. The main complications are pancreatitis (2-7%), post sphincterotomy bleeding (1-2%), impaired function of the sphincter with reflux of duodenal content to the bile ducts and a consecutive risk for cholangitis, stone recurrence and even a potential higher risk for cholangiocarcinoma.
The aim of this study is to evaluate an alternative surgical approach of bile duct clearance at the time of cholecystectomy. Literature of this approach is scarce; however, it has shown a trend to lower postoperative complications if compared to ERC. The technique of sphincter of Oddi balloon dilatation and bile duct clearance from stones via cystic duct at cholecystectomy has been described in a few case series. These small case series have shown a good success rate of bile stone clearance and low complication rates when applying the balloon dilation technique for smaller stones.
The investigators have used this technique in selected cases with good success as well. However, the technique needs to be assessed regarding feasibility and safety in a consecutive group of patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Trans cystic papillary ballon dilatation during cholecystectomy
Time frame: During operation, up to 2 hours
Intraoperative cholangiogram showing no persistent stones in the common bile duct after the study procedure
Time frame: At the 6 week follow up appointment
Patient not showing any signs of choledocholithiasis (fever, pale stool, dark urine, right upper quadrant pain, elevated cholestasis parameters) at 6 week follow up
Time frame: During operation, up to 2 hours
Injury to common bile duct is defined as contrast agent leakage from common bile duct during cholangiography or an obvious lesion.
Time frame: During operation, up to 2 hours
Measured in ml
Time frame: During operation, up to 2 hours
Number of erythrocyte concentrates (275ml each)
Time frame: During operation, up to 2 hours
stomach, duodenum, liver, small bowel, colon
Time frame: From operation up to 6 weeks postoperative
Bile leakage is defined as bilirubin concentration in the drain fluid at least 3 times the serum bilirubin concentration on or after postoperative day 3 or as the need for radiologic or operative intervention resulting from biliary collections or biliary peritonitis
Time frame: From operation up to 6 weeks postoperative
Significant bleeding is defined as a drop in haemoglobin level > 3 g/dl post-operatively compared with the post-operative baseline level and/or any post-operative transfusion of packed red blood cells for a falling haemoglobin and/or the need for radiological intervention (such as embolization) and/or re-operation to stop bleeding
Time frame: From operation up to 6 weeks postoperative
Cholangitis is defined according to the Tokyo Guidelines 2018 [17]: The guidelines encompass systemic TCPBD-Pilot-Tr ial Version 4.0 of 14.09.2020 Page 29 of 41 inflammation (fever, chills or increased inflammatory markers), cholestasis (jaundice or abnormal liver function tests) and imaging (biliary dilation or evidence of stricture, stone or stent). Diagnosis can be suspected in cases of systemic inflammation and one of the two other parameters. Diagnosis is confirmed if all three parameters are present.
Time frame: 4 hours after the operation
Lipasaemia is defined as elevation in serum lipase to ten times or greater than the upper limit of normal. It is measured 4 hours after the intervention
Time frame: From operation up to 6 weeks postoperative
The diagnosis of acute pancreatitis is defined by the presence of two of the following three criteria: acute onset of persistent, severe, epigastric pain often radiating to the back, elevation in serum lipase or amylase to three times or greater than the upper limit of normal, and characteristic findings of acute pancreatitis on imaging (contrast-enhanced computed tomography, magnetic resonance imaging, or transabdominal ultrasonography)
Insel Gruppe AG, University Hospital Bern
Other
Feasibility and Safety of Intraoperative Bile Duct Clearance by Sphincter of Oddi Balloon Dilatation: A Prospective Observational Pilot Study
Acronym: TCPBD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06676241
Acute Pancreatitis (AP), Bile Duct Diseases
Moscow, Moscow Oblast, Russia
View Trial DetailsNCT06672991
Bile Duct Diseases, Biliary Tract Diseases
Moscow, Moscow Oblast, Russia
View Trial DetailsNCT04052633
Bile Duct Diseases, Biliary Tract Diseases
Jyväskylä, Finland
View Trial DetailsNCT01824186
Bile Duct Diseases, Biliary Tract Diseases
Singapore
View Trial Details